By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its fourth-quarter molecular diagnostics sales rose around 11 percent year over year to $126 million from $114 million in Q4 2010.

The Abbot Park, Ill.-based diagnostics and pharmaceuticals giant reported total sales of $10.38 billion for the quarter, up 4 percent from $9.97 billion. Its net earnings for the quarter were $1.62 billion, or $1.02 per share, up from $1.44 billion, or $.92 per share, for the fourth quarter of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.